LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article ; Online: Vaccine Effectiveness Against Influenza-Associated Hospitalizations Among Adults, 2018-2019, US Hospitalized Adult Influenza Vaccine Effectiveness Network.

    Ferdinands, Jill M / Gaglani, Manjusha / Ghamande, Shekhar / Martin, Emily T / Middleton, Donald / Monto, Arnold S / Silveira, Fernanda / Talbot, Helen K / Zimmerman, Richard / Smith, Emily R / Patel, Manish

    The Journal of infectious diseases

    2020  Volume 224, Issue 1, Page(s) 151–163

    Abstract: We estimated vaccine effectiveness (VE) for prevention of influenza-associated hospitalizations among adults during the 2018-2019 influenza season. Adults admitted with acute respiratory illness to 14 hospitals of the US Hospitalized Adult Influenza ... ...

    Abstract We estimated vaccine effectiveness (VE) for prevention of influenza-associated hospitalizations among adults during the 2018-2019 influenza season. Adults admitted with acute respiratory illness to 14 hospitals of the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN) and testing positive for influenza were cases; patients testing negative were controls. VE was estimated using logistic regression and inverse probability of treatment weighting. We analyzed data from 2863 patients with a mean age of 63 years. Adjusted VE against influenza A(H1N1)pdm09-associated hospitalization was 51% (95% confidence interval [CI], 25%-68%). Adjusted VE against influenza A(H3N2) virus-associated hospitalization was -2% (95% CI, -65% to 37%) and differed significantly by age, with VE of -130% (95% CI, -374% to -27%) among adults 18 to ≤56 years of age. Although vaccination halved the risk of influenza A(H1N1)pdm09-associated hospitalizations, it conferred no protection against influenza A(H3N2)-associated hospitalizations. We observed negative VE for young and middle-aged adults but cannot exclude residual confounding as a potential explanation.
    MeSH term(s) Adolescent ; Adult ; Aged ; Aged, 80 and over ; Female ; Hospitalization ; Humans ; Influenza Vaccines/immunology ; Logistic Models ; Male ; Middle Aged ; Vaccination ; Young Adult
    Chemical Substances Influenza Vaccines
    Language English
    Publishing date 2020-12-18
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, U.S. Gov't, P.H.S.
    ZDB-ID 3019-3
    ISSN 1537-6613 ; 0022-1899
    ISSN (online) 1537-6613
    ISSN 0022-1899
    DOI 10.1093/infdis/jiaa772
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh II Zs.50: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 445: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults.

    Keitel, Wendy A / Dekker, Cornelia L / Mink, ChrisAnna / Campbell, James D / Edwards, Kathryn M / Patel, Shital M / Ho, Dora Y / Talbot, Helen K / Guo, Kuo / Noah, Diana L / Hill, Heather

    Vaccine

    2009  Volume 27, Issue 47, Page(s) 6642–6648

    Abstract: Dosage-sparing strategies, adjuvants and alternative substrates for vaccine production are being explored for influenza vaccine development. We assessed the safety and immunogenicity of a Vero cell culture-grown inactivated whole virus influenza A/H5N1 ... ...

    Abstract Dosage-sparing strategies, adjuvants and alternative substrates for vaccine production are being explored for influenza vaccine development. We assessed the safety and immunogenicity of a Vero cell culture-grown inactivated whole virus influenza A/H5N1 vaccine with or without aluminum hydroxide adjuvant [Al(OH)(3)] in healthy young adults. Vaccines were well tolerated, but injection site discomfort was more frequent in groups receiving Al(OH)(3). Dose-related increases in serum antibody levels were observed. Neutralizing antibody titers varied significantly when tested by two different laboratories. Al(OH)(3) did not enhance HAI or neutralizing antibody responses, and contributed to increased injection site pain. Because influenza antibody titers vary significantly between different laboratories, international standardization of assays is warranted.
    MeSH term(s) Adjuvants, Immunologic/administration & dosage ; Adjuvants, Immunologic/adverse effects ; Adolescent ; Adult ; Aluminum Hydroxide/administration & dosage ; Aluminum Hydroxide/adverse effects ; Animals ; Antibodies, Viral/blood ; Chlorocebus aethiops ; Dose-Response Relationship, Immunologic ; Double-Blind Method ; Female ; Hemagglutination Inhibition Tests ; Humans ; Influenza A Virus, H5N1 Subtype/immunology ; Influenza Vaccines/administration & dosage ; Influenza Vaccines/adverse effects ; Influenza Vaccines/immunology ; Influenza, Human/immunology ; Influenza, Human/prevention & control ; Male ; Neutralization Tests/standards ; Vero Cells ; Young Adult
    Chemical Substances Adjuvants, Immunologic ; Antibodies, Viral ; Influenza Vaccines ; Aluminum Hydroxide (5QB0T2IUN0)
    Language English
    Publishing date 2009-03-25
    Publishing country Netherlands
    Document type Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, N.I.H., Extramural
    ZDB-ID 605674-x
    ISSN 1873-2518 ; 0264-410X
    ISSN (online) 1873-2518
    ISSN 0264-410X
    DOI 10.1016/j.vaccine.2009.03.015
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1930: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 458: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults.

    Bernstein, David I / Edwards, Kathryn M / Dekker, Cornelia L / Belshe, Robert / Talbot, Helen K B / Graham, Irene L / Noah, Diana L / He, Fenhua / Hill, Heather

    The Journal of infectious diseases

    2008  Volume 197, Issue 5, Page(s) 667–675

    Abstract: Background: Influenza A H5N1 viruses pose a significant threat to human health.: Methods: We conducted a multicenter, randomized, double-blind study in 394 healthy adults. Subjects were randomly assigned to receive 2 intramuscular doses of either ... ...

    Abstract Background: Influenza A H5N1 viruses pose a significant threat to human health.
    Methods: We conducted a multicenter, randomized, double-blind study in 394 healthy adults. Subjects were randomly assigned to receive 2 intramuscular doses of either saline placebo; influenza A/Vietnam/1203/2004(H5N1) vaccine alone at 45, 30, or 15 microg per dose; vaccine at 15 or 7.5 microg per dose with MF59; or vaccine at 30, 15, or 7.5 microg per dose with aluminum hydroxide. Subjects were followed up for safety and blood samples were obtained to determine antibody responses.
    Results: The vaccine formulations were well tolerated but local adverse effects were common; the incidence of these effects increased in a dose-dependent manner and was increased by the addition of adjuvants. The addition of MF59 increased the antibody response, whereas the addition of aluminum hydroxide did not. The highest antibody responses were seen in the group that received 15 microg of vaccine per dose with MF59, in which 63% of subjects achieved the predetermined endpoint (hemagglutination-inhibition titer > or =40) 28 days after the second dose, compared with 29% in the group that received the highest dose (45 microg per dose) of vaccine alone.
    Conclusions: A 2-dose regimen of subvirion influenza A (H5N1) vaccine was well tolerated. The antibody responses to 15 microg of A/H5 vaccine with MF59 were higher than the responses to 45 microg of vaccine alone.
    Trial registration: ClincalTrials.gov identifier: http://www.clinicaltrials.gov/ct2/show/NCT00280033?term= NCT00280033&rank=1 NCT00280033 .
    MeSH term(s) Adjuvants, Immunologic/administration & dosage ; Adjuvants, Immunologic/adverse effects ; Adolescent ; Adult ; Aluminum Hydroxide/administration & dosage ; Aluminum Hydroxide/adverse effects ; Aluminum Hydroxide/immunology ; Antibodies, Viral/blood ; Dose-Response Relationship, Immunologic ; Double-Blind Method ; Female ; Humans ; Immunization Schedule ; Influenza A Virus, H5N1 Subtype/immunology ; Influenza Vaccines/adverse effects ; Influenza Vaccines/immunology ; Influenza, Human/prevention & control ; Male ; Middle Aged ; Polysorbates/adverse effects ; Squalene/adverse effects ; Squalene/immunology
    Chemical Substances Adjuvants, Immunologic ; Antibodies, Viral ; Influenza Vaccines ; MF59 oil emulsion ; Polysorbates ; Aluminum Hydroxide (5QB0T2IUN0) ; Squalene (7QWM220FJH)
    Language English
    Publishing date 2008-03-01
    Publishing country United States
    Document type Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, N.I.H., Extramural
    ZDB-ID 3019-3
    ISSN 1537-6613 ; 0022-1899
    ISSN (online) 1537-6613
    ISSN 0022-1899
    DOI 10.1086/527489
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh II Zs.50: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 445: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Human coronavirus NL63 is not detected in the respiratory tracts of children with acute Kawasaki disease.

    Shimizu, Chisato / Shike, Hiroko / Baker, Susan C / Garcia, Francesca / van der Hoek, Lia / Kuijpers, Taco W / Reed, Sharon L / Rowley, Anne H / Shulman, Stanford T / Talbot, Helen K B / Williams, John V / Burns, Jane C

    The Journal of infectious diseases

    2005  Volume 192, Issue 10, Page(s) 1767–1771

    Abstract: Kawasaki disease (KD) is a self-limited, systemic vasculitis of children for which an infectious trigger is suspected. Recently, an association between KD and human coronavirus (HCoV)-New Haven (NH) was reported, on the basis of polymerase chain reaction ...

    Abstract Kawasaki disease (KD) is a self-limited, systemic vasculitis of children for which an infectious trigger is suspected. Recently, an association between KD and human coronavirus (HCoV)-New Haven (NH) was reported, on the basis of polymerase chain reaction (PCR) with primers that also amplified HCoV-NL63. We investigated the possible association between these HCoVs in the respiratory tract and KD by reverse-transcriptase (RT) PCR and viral culture in a geographically and ethnically diverse population. Only 1 (2%) of 48 patients with acute KD was positive by RT-PCR for HCoV-NL63/NH in a nasopharyngeal swab. These data do not support an association between these HCoVs and KD.
    MeSH term(s) Child ; Child, Preschool ; Coronavirus/genetics ; Coronavirus/isolation & purification ; Coronavirus Infections/complications ; Coronavirus Infections/virology ; Female ; Humans ; Infant ; Male ; Mucocutaneous Lymph Node Syndrome/virology ; Respiratory System/virology ; Reverse Transcriptase Polymerase Chain Reaction ; Virus Cultivation
    Keywords covid19
    Language English
    Publishing date 2005-10-17
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 3019-3
    ISSN 1537-6613 ; 0022-1899
    ISSN (online) 1537-6613
    ISSN 0022-1899
    DOI 10.1086/497170
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh II Zs.50: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 445: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online ; Conference proceedings: Workshop on immunizations in older adults: identifying future research agendas.

    High, Kevin P / D'Aquila, Richard T / Fuldner, Rebecca A / Gerding, Dale N / Halter, Jeffrey B / Haynes, Laura / Hazzard, William R / Jackson, Lisa A / Janoff, Edward / Levin, Myron J / Nayfield, Susan G / Nichol, Kristin L / Prabhudas, Mercy / Talbot, Helen K / Clayton, Charles P / Henderson, Randi / Scott, Catherine M / Tarver, Erika D / Woolard, Nancy F /
    Schmader, Kenneth E

    Journal of the American Geriatrics Society

    2010  Volume 58, Issue 4, Page(s) 765–776

    Abstract: Goals for immunization in older adults may differ from those in young adults and children, in whom complete prevention of disease is the objective. Often, reduced hospitalization and death but also averting exacerbation of underlying chronic illness, ... ...

    Abstract Goals for immunization in older adults may differ from those in young adults and children, in whom complete prevention of disease is the objective. Often, reduced hospitalization and death but also averting exacerbation of underlying chronic illness, functional decline, and frailty are important goals in the older age group. Because of the effect of age on dendritic cell function, T cell-mediated immune suppression, reduced proliferative capacity of T cells, and other immune responses, the efficacy of vaccines often wanes with advanced age. This article summarizes the discussion and proceedings of a workshop organized by the Association of Specialty Professors, the Infectious Diseases Society of America, the American Geriatrics Society, the National Institute on Aging, and the National Institute of Allergy and Infectious Diseases. Leading researchers and clinicians in the fields of immunology, epidemiology, infectious diseases, geriatrics, and gerontology reviewed the current status of vaccines in older adults, identified knowledge gaps, and suggest priority areas for future research. The goal of the workshop was to identify what is known about immunizations (efficacy, effect, and current schedule) in older adults and to recommend priorities for future research. Investigation in the areas identified has the potential to enhance understanding of the immune process in aging individuals, inform vaccine development, and lead to more-effective strategies to reduce the risk of vaccine-preventable illness in older adults.
    MeSH term(s) Adaptive Immunity/immunology ; Aged/physiology ; Aging/immunology ; Antigen-Presenting Cells/immunology ; B-Lymphocytes/immunology ; Centers for Disease Control and Prevention (U.S.) ; Evidence-Based Practice/organization & administration ; Forecasting ; Geriatrics/organization & administration ; Health Planning Guidelines ; Health Services Needs and Demand ; Humans ; Immunization Schedule ; Research/organization & administration ; T-Lymphocytes/immunology ; Telomere/immunology ; United States ; Vaccination/methods
    Language English
    Publishing date 2010-04
    Publishing country United States
    Document type Congresses ; Research Support, Non-U.S. Gov't
    ZDB-ID 80363-7
    ISSN 1532-5415 ; 0002-8614
    ISSN (online) 1532-5415
    ISSN 0002-8614
    DOI 10.1111/j.1532-5415.2010.02772.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ud II Zs.168: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top